Physician profile
Hannah Hill
NPI 1679928519
$13,189.08
in general payments reported to CMS, 2019-2025
29 companies · $4,903 in 2025
The $4,903 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $266 · 2021: $1,356 · 2022: $2,011 · 2023: $2,078 · 2024: $2,325 · 2025: $4,903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,066 · Consulting Fee: $2,040 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,066.18 |
| Consulting Fee | $2,040.00 |
| Education | $199.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $2,630.18 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $1,956.83 | 2021-2025 | Dupixent, Libtayo |
| Abbvie INC. | $1,308.92 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $1,044.34 | 2020-2025 | |
| Janssen Biotech, INC. | $869.14 | 2020-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $734.55 | 2020-2025 | |
| Leo Pharma INC. | $705.45 | 2021-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $588.50 | 2020-2025 | Odomzo, Blu-U, Ilumya |
| Lilly USA, LLC | $470.30 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $398.12 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $364.50 | 2021-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $301.11 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $292.12 | 2020-2024 | Jublia |
| Mayne Pharma Commercial LLC | $227.15 | 2022-2025 | |
| Ucb, INC. | $216.67 | 2020-2025 | Bimzelx, Cimzia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $142.60 | 2021-2025 | Seysara, Klisyri |
| Amgen INC. | $136.93 | 2024-2025 | Otezla, Otezla |
| Vyne Pharmaceuticals INC. | $126.37 | 2020-2021 | |
| Allergan, INC. | $125.01 | 2019 | |
| Arcutis Biotherapeutics, INC. | $113.47 | 2023-2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $87.28 | 2023-2025 | Ycanth |
| Dermavant Sciences, INC. | $80.18 | 2023-2024 | Vtama |
| Revance Therapeutics, INC. | $67.78 | 2025 | Daxxify |
| Organon LLC | $57.54 | 2025 | Vtama, Nexplanon |
| Biofrontera INC. | $51.33 | 2021-2022 | |
| Epi Health, LLC | $40.96 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.77 | 2023 | Spevigo |
| Journey Medical Corporation | $16.48 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.